These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29069110)

  • 1. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition.
    Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS
    Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms.
    Soares CN; Frey BN; Haber E; Steiner M
    J Clin Psychopharmacol; 2010 Oct; 30(5):612-5. PubMed ID: 20814317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
    Freeman MP; Hirschberg AM; Wang B; Petrillo LF; Connors S; Regan S; Joffe H; Cohen LS
    Maturitas; 2013 Jun; 75(2):170-4. PubMed ID: 23602542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial.
    Freeman MP; Hibbeln JR; Silver M; Hirschberg AM; Wang B; Yule AM; Petrillo LF; Pascuillo E; Economou NI; Joffe H; Cohen LS
    Menopause; 2011 Mar; 18(3):279-84. PubMed ID: 21037490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
    Baldwin DS; Hansen T; Florea I
    Curr Med Res Opin; 2012 Oct; 28(10):1717-24. PubMed ID: 22978748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC; Chang TS; Chen C; Sung JY
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
    [No Abstract]   [Full Text] [Related]  

  • 17. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC; Schmidt SN; Grande I
    J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L; Bocharova M; Young AH; Aarsland D
    J Affect Disord; 2024 Sep; 361():74-81. PubMed ID: 38838790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.